PolyActiva Expands Executive Team to Drive Transformational Growth and Advance Late-Stage Clinical Development in the U.S.

FORT WORTH, Texas & MELBOURNE, Australia--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced the appointments of Wes Brazell as Chief Financial Officer (CFO) and Michael Brubaker, PhD, as Chief Scientific Officer (CSO). “Wes and Mike bring exceptional expertise in their respective fields and a shared commitment to innovation and value creation in ophthalmolog